Radiodermatitis Market Size, Share, Growth, Forecast 2030

Radiodermatitis Market Size And Industry Analysis

The global radiodermatitis market size was worth USD 521.30 million in 2021 and is estimated to grow to USD 655.81 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.9 percent over the forecast period. The report analyses the smart hospitals market's drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the radiodermatitis market.

Request Free Sample

Radiodermatitis Market: Overview

One of the most widely used cancer therapies, radiotherapy, frequently results in radiation dermatitis. The degree of radiation dermatitis might vary. While some individuals may only have minor redness and itching, others may endure painful, damaged skin prone to infection. Depending on the radiation dose and the patient's skin sensitivity, radiation dermatitis symptoms generally appear days or weeks after beginning radiotherapy. Melanocytes, hair follicle stem cells, and basal keratinocytes are radiosensitive.

The first fractionated dosage of radiation during radiation therapy results in immediate structural tissue damage, cellular water ionization, and the production of short-lived free radicals, irreversible double-stranded breaks in nuclear and mitochondrial DNA, and inflammation. The rising number of patients experiencing radiodermatitis as a side effect of radiation therapy is the main factor driving the market. The need for radiodermatitis treatment items is now more urgent than ever because of the need to stop this negative consequence. As a result, there has been a discernible rise in the use of radiodermatitis products to enhance the quality of life, which has sped up market development.

COVID-19 Impact:

Every element of healthcare delivery, including cancer treatment, has been affected by the COVID-19 epidemic. The current coronavirus pandemic has a moderate impact on the radiodermatitis market. As one of the few viable treatment modalities for cancer, radiation therapy requires hospital visits; therefore, cancer patients represent a high-risk group during the pandemic. Leading cancer institutions claimed that radiotherapy was the most effective and secure treatment option during the COVID-19 pandemic. Radiation dermatitis, in contrast, is a frequent side effect of radiotherapy, which can harm skin cells while treating cancer cells. As a result, it is projected that demand for products to treat radiodermatitis will rise concurrently, further fueling market expansion. The radiodermatitis market is anticipated to see a downturn during the forecast period due to problems with product supply for several radiodermatitis producers.

Request Free Sample

Key Insights

• As per the analysis shared by our research analyst, the global radiodermatitis market value will grow at a CAGR of 3.9% over the forecast period. 
• In terms of revenue, the global radiodermatitis market size was valued at around USD 521.30 million in 2021 and is projected to reach USD 655.81 million by 2028. 
• One of the major factors driving this market is the growing number of governmental and private healthcare organizations actively working to raise knowledge about the management and treatment of radiodermatitis.
• By product, the topical category dominated the market in 2021.
• By distribution channel, the retail pharmacy category dominated the market in 2021.
• North America dominated the global radiodermatitis market in 2021.

Radiodermatitis Market: Growth Drivers

An increase in research and development advancements to drive market growth

The market for radiodermatitis is also anticipated to grow due to increased emphasis on research to identify suitable standard treatments. The market's lack of standard care goods creates a highly favorable situation for players to launch their novel product concepts on the road to success. Cancer patients receiving radiation therapy or a chemotherapy and radiation therapy combination may develop radiodermatitis, a skin disorder.

Radiodermatitis Market: Restraints

High radiodermatitis cost is hindering the market growth.

In developing countries, where expensive therapy causes budget limits, the burden of cancer treatment is a worry. As a result, the global radiodermatitis market is expected to be constrained by expensive items, particularly dressings like honey-impregnated dressings and silicone dressings. Furthermore, the expansion of branded and pricey dressings is predicted to be hampered by the accessibility of inexpensive locally manufactured dressings in emerging nations.

Radiodermatitis Market: Opportunity

Significant healthcare facility expansion in Asia-Pacific to generate investment opportunities

In the past few years, biotechnology & pharmaceutical industries have seen a noticeable expansion in Asian nations like India, Japan, China, and Singapore. In addition, Asian consumers are becoming increasingly conscious of ways to improve their quality of life. Additionally, the burden of numerous chronic illnesses, such as breast and skin cancer, is drastically rising throughout the APAC region. As a result, radiodermatitis consumption and growth have increased in this region, which could present market prospects for the radiodermatitis industry globally throughout the projection period.

Radiodermatitis Market: Segmentation

The global radiodermatitis market has been segmented into product, distribution channels, and region.

Based on product, the market is classified into topical, oral, and dressings. In 2021, the topical category dominated the global market. A significant portion is thought to result from the advantages of topical products. These advantages, anticipated to be some of the primary driving forces behind the acceptance of these items throughout the previous years, include ease of use, accessibility, and great cost-efficiency. Topical treatments also reduce microbiological transfer and protect the skin from abrasive substances. Some key items under this category are topical antibiotics, hydrophilic lotions, and corticosteroids.

Based on distribution channels, the global radiodermatitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies based on application type. Retail pharmacies are anticipated to have the highest share in this market. The significant percentage can be attributable to the high accessibility and cost of retail stores. Drug cost reimbursement encourages patients to rely on retail pharmacies, which increases market growth potential due to affordability. Due to several benefits, including greater convenience for customers who don't want to buy medications from retail or hospital pharmacies, online pharmacies are predicted to experience exponential development over the projection period. Furthermore, there is a gap between the supply and demand of very important pharmaceuticals due to the increasing frequency of chronic diseases. These factors will increase the demand for online pharmacies throughout the projected period.

Recent Developments

• April 2019: To increase their focus on wound care for radiation therapy patients, CIVCO Radiotherapy and Stratpharma AG collaborated in April 2019. CIVCO Radiotherapy is an expert in providing high-quality, patient-centric radioactive solutions. This is probably going to emphasize patient-centered treatment and enhance postoperative results.
• July 2017: StrataXRT, the first and only topical film wound dressing for radiation dermatitis, was introduced by Stratpharma AG in July 2017. This product promotes quick recovery and helps people who have had radiation therapy. It is unique and adaptable.

Radiodermatitis Market: Report Scope

Radiodermatitis Market: Competitive Landscape 

Some of the main competitors dominating the global radiodermatitis market include- The 3M Company, Bayer Ag., Bausch Health Companies Inc., BMG Pharma S.P.A., Convatec Group PLC., Glaxosmithkline PLC, Helsinn Healthcare SA, Molnlycke Health Care AB, Mylan N.V., Stratpharma Ag, Smith & Nephew PLC.

Radiodermatitis Market: Regional Landscape

North America was the fastest growing region in the radiodermatitis market in 2021

Due to the rising prevalence of cancer-causing disorders, North America is the region in the world market for radiodermatitis that is expanding the fastest. Additionally, it is anticipated that the strong market share of Cardinal Health, 3M, and Mylan N.V., along with their cutting-edge product advancements, would favorably affect the global radiodermatitis market throughout the study period.

Request Free Sample

In 2021, the Asia-Pacific region accounted for a significant portion of the global radiodermatitis market, largely due to rising disposable income, an increase in cancer incidence, widespread use of cutting-edge medical products, and rising spending on healthcare infrastructure. Additionally, the rising demand for radiation therapy, particularly in China, Japan, and India, along with the inclusion of radiodermatitis medications in healthcare reimbursements, may propel the Asia-Pacific radiodermatitis market in the years to come.

Radiodermatitis Market: Competitive Space

The global Radiodermatitis market profiles key players such as:

• The 3M Company
• Bayer Ag
• Bausch Health Companies Inc
• BMG Pharma S.P.A
• Convatec Group PLC
• Glaxosmithkline PLC
• Helsinn Healthcare SA
• Molnlycke Health Care AB
• Mylan N.V.
• Stratpharma Ag
• Smith & Nephew PLC

The global Radiodermatitis Market is segmented as follows:

By Product

• Topical
• Oral Drugs
• Dressings

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa